Literature DB >> 26854325

Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Irene Litvan1,2, Peter S J Lees3, Christopher R Cunningham1, Shesh N Rai4, Alexander C Cambon4, David G Standaert5, Connie Marras6, Jorge Juncos7, David Riley8, Stephen Reich9, Deborah Hall10,11, Benzi Kluger11, Yvette Bordelon12, David R Shprecher13.   

Abstract

BACKGROUND: The cause of progressive supranuclear palsy (PSP) is largely unknown. Based on evidence for impaired mitochondrial activity in PSP, we hypothesized that the disease may be related to exposure to environmental toxins, some of which are mitochondrial inhibitors.
METHODS: This multicenter case-control study included 284 incident PSP cases of 350 cases and 284 age-, sex-, and race-matched controls primarily from the same geographical areas. All subjects were administered standardized interviews to obtain data on demographics, residential history, and lifetime occupational history. An industrial hygienist and a toxicologist unaware of case status assessed occupational histories to estimate past exposure to metals, pesticides, organic solvents, and other chemicals.
RESULTS: Cases and controls were similar on demographic factors. In unadjusted analyses, PSP was associated with lower education, lower income, more smoking pack-years, more years of drinking well water, more years living on a farm, more years living 1 mile from an agricultural region, more transportation jobs, and more jobs with exposure to metals in general. However, in adjusted models, only more years of drinking well water was significantly associated with PSP. There was an inverse association with having a college degree.
CONCLUSIONS: We did not find evidence for a specific causative chemical exposure; higher number of years of drinking well water is a risk factor for PSP. This result remained significant after adjusting for income, smoking, education and occupational exposures. This is the first case-control study to demonstrate PSP is associated with environmental factors.
© 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  case-control study; epidemiology; parkinsonism; progressive supranuclear palsy; risk factors

Mesh:

Year:  2016        PMID: 26854325      PMCID: PMC4861658          DOI: 10.1002/mds.26512

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  31 in total

1.  Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms.

Authors:  N Vanacore; V Bonifati; G Fabbrini; C Colosimo; R Marconi; D Nicholl; U Bonuccelli; F Stocchi; P Lamberti; G Volpe; G De Michele; I Iavarone; P Bennett; P Vieregge; G Meco
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

3.  Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.

Authors:  J H Bower; D M Maraganore; S K McDonnell; W A Rocca
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

4.  Smoking and Parkinson's disease. An age-dependent risk effect? The EUROPARKINSON Study Group.

Authors:  C Tzourio; W A Rocca; M M Breteler; M Baldereschi; J F Dartigues; S Lopez-Pousa; J M Manubens-Bertran; A Alpérovitch
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

5.  Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.

Authors:  D S Albers; S J Augood; D M Martin; D G Standaert; J P Vonsattel; M F Beal
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

6.  A geographical cluster of progressive supranuclear palsy in northern France.

Authors:  Dominique Caparros-Lefebvre; Lawrence I Golbe; Vincent Deramecourt; Claude-Alain Maurage; Vincent Huin; Valerie Buée-Scherrer; Helene Obriot; Bernard Sablonnière; Francois Caparros; Luc Buée; Andrew J Lees
Journal:  Neurology       Date:  2015-09-09       Impact factor: 9.910

7.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.

Authors:  O L Lopez; I Litvan; K E Catt; R Stowe; W Klunk; D I Kaufer; J T Becker; S T DeKosky
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

8.  Risk factors for progressive supranuclear palsy: a case-control study in France.

Authors:  J-S Vidal; M Vidailhet; P Derkinderen; T Dubard de Gaillarbois; C Tzourio; A Alpérovitch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-11       Impact factor: 10.154

9.  Professional exposure to pesticides and Parkinson disease.

Authors:  Alexis Elbaz; Jacqueline Clavel; Paul J Rathouz; Frédéric Moisan; Jean-Philippe Galanaud; Bernard Delemotte; Annick Alpérovitch; Christophe Tzourio
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

10.  Validation of a telephone questionnaire for Parkinson's disease.

Authors:  W A Rocca; D M Maraganore; S K McDonnell; D J Schaid
Journal:  J Clin Epidemiol       Date:  1998-06       Impact factor: 6.437

View more
  11 in total

Review 1.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

2.  Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Authors:  Hee Kyung Park; Sindana Ilango; Christina M Charriez; Harvey Checkoway; David Riley; David G Standaert; Yvette Bordelon; David R Shprecher; Stephen G Reich; Deborah Hall; Benzi Kluger; Connie Marras; Joseph Jankovic; Richard Dubinsky; Irene Litvan
Journal:  Mov Disord       Date:  2018-02-20       Impact factor: 10.338

3.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Progressive Supranuclear Palsy and Statin Use.

Authors:  Ece Bayram; Connie Marras; David G Standaert; Benzi M Kluger; Yvette M Bordelon; David R Shprecher; Irene Litvan
Journal:  Mov Disord       Date:  2020-03-27       Impact factor: 10.338

5.  Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Authors:  Ali Shoeibi; Irene Litvan; Jorge L Juncos; Yvette Bordelon; David Riley; David Standaert; Stephen G Reich; David Shprecher; Deborah Hall; Connie Marras; Benzi Kluger; Nahid Olfati; Joseph Jankovic
Journal:  Parkinsonism Relat Disord       Date:  2019-10-14       Impact factor: 4.891

Review 6.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

7.  18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.

Authors:  Luca Passamonti; Patricia Vázquez Rodríguez; Young T Hong; Kieren S J Allinson; David Williamson; Robin J Borchert; Saber Sami; Thomas E Cope; W Richard Bevan-Jones; P Simon Jones; Robert Arnold; Ajenthan Surendranathan; Elijah Mak; Li Su; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

8.  Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans.

Authors:  Kristen D Kelley; Harvey Checkoway; Deborah A Hall; Stephen G Reich; Chris Cunningham; Irene Litvan
Journal:  Front Neurol       Date:  2018-06-20       Impact factor: 4.003

Review 9.  Frontrunner in Translation: Progressive Supranuclear Palsy.

Authors:  Ali Shoeibi; Nahid Olfati; Irene Litvan
Journal:  Front Neurol       Date:  2019-10-22       Impact factor: 4.003

10.  Outlining a Population "at Risk" of Parkinson's Disease: Evidence from a Case-Control Study.

Authors:  Tommaso Schirinzi; Giuseppina Martella; Alessio D'Elia; Giulia Di Lazzaro; Paola Imbriani; Graziella Madeo; Leonardo Monaco; Marta Maltese; Antonio Pisani
Journal:  Parkinsons Dis       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.